The latest breakthroughs in Adaptive Designs in Clinical Trials

Share Article

Adaptive Designs in Clinical Trials to take place in London, UK, 8th & 9th April 2013

Clinical trials run by pharmaceutical and biotech companies have undergone major changes, implementing adaptive designs to tailor a trial. Reduction in costs and timings of early phase clinical trials can mean lower recruitment of patients and improve the overall clinical accuracy. Successful implementation of adaptive designs into a trial however requires unparalleled coordination between clinicians, trial managers, statisticians and those involved in external and internal regulation.

SMi’s Adaptive Designs in Clinical Trials conference returns to London in April for the 5th year running. Pharma companies of all sizes will disclose how they have successfully implemented trials incorporating adaptive designs. Through their in-depth case studies and presentations delegates will learn how to implement an adaptive design clinical trial for their own drug development, from initial processes in managing trials to choosing the right time to implement change.


  • The motivation, promise, and success of Bayesian adaptive trial design
  • An adaptive design to explore prevention therapies for Alzheimer's Disease
  • Controlling the weighted sum of Type I and Type II errors, and implications for the design and analysis of adaptive designs
  • From preclinical studies to adaptive designs – a path to the future
  • Bayesian Variable Selection (BVS) approach for dose-response modelling
  • Adaptive sample size and modification in clinical trials: start small then ask for more?
  • Adaptive trials in pre-clinical discovery
  • Paediatric adaptation: early (stage) we practice, later perhaps we practice less
  • Designing multi-arm multi-stage clinical trials
  • Exploratory dose finding in malaria

Delegates now registered to attend include: Jazz Pharmaceuticals Inc, Celgene, Novartis, Propharma Partners, University College London, Voisin Consulting, Aptiv Solutions, UCB Pharma, Sanofi Aventis, Roche, Takeda, Boehringer Ingelheim, Oxford University, Tessella Support Services & Office of Health Economics

Recognised as Europe’s only dedicated adaptive designs conference, this year’s event is expected to be the best year yet!

Dale Butler, MD of event organiser SMi reported: 'response to this year's event has been extremely positive thanks to the strength of industry bodies and technology specialists we have on board. We look forward to once again providing a Europe-wide platform for debate and knowledge-sharing amongst our varied communities, both in the lead up to and at the event itself'.

For the full conference programme and further information please visit:
Alternatively contact Cem Tuna on +44 (0)20 7827 6736 or email him at ctuna(at)smi-online(dot)

About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.
For more information, please visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sonal Patel
Follow us on
Visit website